Securing long-term supply advances development of Company’s proprietary VMT-𝛼-
GEN isotope generator which enables a nimble supply of therapeutic radioisotopes with
the power of alpha-particle therapy for cancer
Coralville, IA, February 18, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into an agreement with the National Isotope Development Center (NIDC) for the long-term supply of parent feedstock radionuclide Th-228 for the manufacturing of the Company’s Ra-224/Pb-212 generator, VMT-𝛼-GEN. The long-term agreement provides deliveries from 2021 through 2030.
In order to build a fully integrated alpha-particle radiopharmaceutical business, Viewpoint is securing the supply of therapeutic Pb-212 radioisotope for medical centers and regional radiopharmacies. To achieve this distinction, Viewpoint is developing its own proprietary benchtop production device (VMT-𝛼-GEN) for delivering alpha-particle therapeutic isotope Pb-212. With a half-life of 10.6 hours, Pb-212 is ideally suited to deliver powerful alpha-particle therapy to cancerous tumors, while representing a lower risk for off-target unintended effects and the potential for treatment on an outpatient basis.
Michael Schultz, PhD, Chief Science Officer of Viewpoint commented, “This agreement is an important step that helps to de-risk our programs by providing a secure supplier of commercial levels of feedstock radionuclide Th-228, a raw material that is necessary for the production VMT-𝛼-GEN. It also secures our position in building a fully-integrated alpha-particle radiopharmaceutical business with cancer targeted ligands at preclinical and clinical stages of development.”
Radionuclide generators such as VMT-𝛼-GEN are used commonly in radiopharmacies and nuclear medicine facilities across the world. The devices share a common characteristic of enabling the production of a purified chemical form of the radionuclide needed that can be easily combined with ligands that seek out cancerous tumors. Because the shelf life of VMT-𝛼-GEN is based on a longer-lived radionuclide (Ra-224), a single shipment of VMT-𝛼-GEN can be used to produce radiopharmaceutical doses daily, for up to a week or more. The device can then be returned to the manufacturer in approved packaging to eliminate radioactive waste from the medical center or radiopharmacy.
Click here for full media release.